Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04020328
Recruitment Status : Recruiting
First Posted : July 16, 2019
Last Update Posted : February 18, 2020
Sponsor:
Information provided by (Responsible Party):
XUYI, Shenzhen Second People's Hospital

Brief Summary:

IgA nephropathy is the most common primary glomerulonephritis in the world. Because of the poor treatment effect in advanced patients, it is still the main cause of maintenance dialysis. Current immunosuppressive therapy is still controversial, especially to those progressive IgA nephropathy with eGFR<50ml/min. Leflunomide is widely used in the treatment of rheumatic diseases, such as rheumatoid arthritis and lupus nephritis, it's serum concentration will not be affected by renal function, and it also has antiviral effect. There are two randomized controlled trials and a retrospective study suggesting that leflunomide combined with glucocorticoids can effectively control urinary protein compared with glucocorticoids or conservative treatment, but these three studies are not specifically targeted at patients with estimated Glomerular Filtration Rate(eGFR) < 50ml/min.

Investigators will perform a prospective, open-label, randomized, controlled trial to evaluate the efficacy and safety of leflunomide and low dose glucocorticoids therapy in progressive IgA nephropathy with eGFR<50ml/min


Condition or disease Intervention/treatment Phase
Glomerulonephritis, IGA Renal Insufficiency, Chronic Drug: Leflunomide 20 mg+prednisone 0.5mg/kg/d Phase 4

Detailed Description:
all the participants enrolled in the study will be randomly assigned in a 1:1 ratio, the experimental group will receive leflunomide + low dose glucocorticoids therapy on the basis of conservative treatment, while the control group receive conservative treatment only. Conservative treatment is defined as the treatment of delaying the progress of renal function, including low-protein diet supplemented with ketoacid therapy, Renin Angiotensin system (RAS) inhibitor, blood pressure control, lipid-regulating therapy and antiplatelet aggregation therapy. The course of treatment will last one year, then the leflunomide+glucocorticoids group will continue the conservative treatment. Participants will be follow-up at least 98 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: the participants who met the inclusion and exclusion criteria were randomly assigned to leflunomide + low dose glucocorticoids treatment group and conservative treatment group in a 1:1 ratio
Masking: None (Open Label)
Masking Description: it is a open label trial
Primary Purpose: Treatment
Official Title: A Randomized, Controlled Trial to Evaluate Leflunomide Plus Low Dose Corticosteroid Therapy in Progressive IgA Nephropathy With Renal Insufficiency
Actual Study Start Date : September 12, 2019
Estimated Primary Completion Date : March 1, 2022
Estimated Study Completion Date : May 31, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: leflunomide + low dose glucocorticoids therapy group
the experimental group will receive leflunomide + low dose glucocorticoids therapy on the basis of conservative treatment, while the control group receive conservative treatment
Drug: Leflunomide 20 mg+prednisone 0.5mg/kg/d
Leflunomide plus low dose glucocorticoids to have the immunosuppressive therapy to those progressive IgA nephropathy with eGFR<50ml/min
Other Name: Arava

No Intervention: Basic conservative treatment group
the basic conservative treatment group is the delaying the progress of renal function, including low-protein diet supplemented with ketoacid therapy, RAS inhibitor, blood pressure control, lipid-regulating therapy and antiplatelet aggregation therapy



Primary Outcome Measures :
  1. renal survival rate [ Time Frame: at least 96 weeks ]
    50% increase in serum creatinine compared with the baseline level or End Stage Renal Disease(ESRD)


Secondary Outcome Measures :
  1. proteinuria [ Time Frame: at least 96 weeks ]
    changes in proteinuria compared to the baseline

  2. eGFR [ Time Frame: at least 96 weeks ]
    extent of eGFR decline compared with the baseline and annual decline rate

  3. complete remission rate [ Time Frame: at least 96 weeks ]
    Complete Remission (CR): proteinuria < 1.0g / 24hr, Scr stable (Scr increase ≤ 15% baseline level)

  4. partial remission rate [ Time Frame: at least 96 weeks ]
    Partial Remission (PR): proteinuria in 1.0-3.5g/24hr range and decrease more than 50%, Scr stable (Scr increased ≤ 15% baseline level)

  5. no response rate [ Time Frame: at least 96 weeks ]
    No Response (NR):proteinuria > 3.5g/24hr or decrease less than 50% of baseline , with or without deterioration of renal function



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   14 Years to 65 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 14 to 65 years old participants, No restrictions on gender or race
  • Diagnosis of primary IgA nephropathy
  • Renal biopsy within 6 months before screening. Renal pathology shows diffuse IgA deposition in the Mesangial area and dense deposition in the Mesangial area under electron microscope. glomeruli more than 8
  • persistent proteinuria ≥ 1 g/24 hr (or urine protein/creatinine ratio ≥ 1.0 mg/g), eGFR at 25-50 ml/min/1.73 m2 (calculated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula)
  • signed written consent; patients under 18 years old need to have legal guardians to sign informed consent at the same time

Exclusion Criteria:

  • Secondary IgA nephropathy (such as lupus nephritis, Henoch-Schönlein purpura, hepatitis B associated glomerulonephritis, hepatitis C associated glomerulonephritis, liver cirrhosis and other autoimmune diseases)
  • eGFR < 25 ml/min/1.73m2 or eGFR > 50 ml/min/1.73m2 (calculated by CKD-EPI formula)
  • Special types of IgA nephropathy need to be excluded, such as crescent IgA glomerulonephritis (defined as the presence of crescents in over 50% of the glomeruli), or minimal lesions with IgA deposition
  • Acute kidney injury within 3 months before screening
  • Received immunosuppressive therapy within 3 months before screening
  • Patients who had acute or chronic infections that need treatment, and the researchers judged that they were not suitable for inclusion in the study
  • Pregnancy, lactation or unreliable birth control
  • Dialysis treatment before screening
  • Allergic or taboo to planned drugs (such as leflunomide, glucocorticoids, etc.)
  • Severe acute or chronic diseases that the researchers believe may bring an excessive risk to the subjects
  • A history of malignant tumors within 5 years, with the exception of carcinoma in situ and papillary thyroid carcinoma which have been adequately treated
  • Participated in other clinical trials and / or used other research drugs within 4 weeks prior to screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04020328


Contacts
Layout table for location contacts
Contact: Yi Xu +8613798309505 xuyi20001234@163.com
Contact: QiJun Wan +8613537857368 yiyuan2224@sina.com

Locations
Layout table for location information
China, Guangdong
Xu Yi Recruiting
Shenzhen, Guangdong, China, 518000
Sponsors and Collaborators
Shenzhen Second People's Hospital
Layout table for additonal information
Responsible Party: XUYI, Principal Investigator, Shenzhen Second People's Hospital
ClinicalTrials.gov Identifier: NCT04020328    
Other Study ID Numbers: 20193357002
First Posted: July 16, 2019    Key Record Dates
Last Update Posted: February 18, 2020
Last Verified: February 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by XUYI, Shenzhen Second People's Hospital:
Leflunomide
Glucocorticoids
Conservative Treatment
Glomerulonephritis, IGA
Renal Insufficiency, Chronic
Additional relevant MeSH terms:
Layout table for MeSH terms
Renal Insufficiency
Glomerulonephritis
Renal Insufficiency, Chronic
Glomerulonephritis, IGA
Kidney Diseases
Urologic Diseases
Nephritis
Autoimmune Diseases
Immune System Diseases
Prednisone
Leflunomide
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors